Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Alkem Laboratories Ltd

Pharmaceuticals & Biotechnology | Mid Cap

Alkem Laboratories Ltd Health Insights
Health Score : 8.08Health Score : 8.08

Alkem Laboratories demonstrates a strong financial position, particularly in solvency, growth, and profitability. The company maintains a healthy balance sheet with low debt levels and robust equity. Revenue and earnings growth are impressive, indicating effective management and market positioning. Profitability metrics, such as ROCE, ROE, and ROA, consistently reflect efficient capital utilization. However, there are some areas of concern, notably in efficiency and liquidity. The company's turnover ratios for fixed assets, inventory, and capital are low, suggesting potential inefficiencies in asset utilization. While the company exhibits high liquidity, its cash flow management needs improvement. Capital expenditure is a key area needing attention, as it impacts overall financial health. Despite these challenges, Alkem's strong performance in core areas positions it well for future growth and stability within the healthcare industry.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Alkem Laboratories Ltd Health Insights
Health Score : 8.08Health Score : 8.08

Alkem Laboratories demonstrates a strong financial position, particularly in solvency, growth, and profitability. The company maintains a healthy balance sheet with low debt levels and robust equity. Revenue and earnings growth are impressive, indicating effective management and market positioning. Profitability metrics, such as ROCE, ROE, and ROA, consistently reflect efficient capital utilization. However, there are some areas of concern, notably in efficiency and liquidity. The company's turnover ratios for fixed assets, inventory, and capital are low, suggesting potential inefficiencies in asset utilization. While the company exhibits high liquidity, its cash flow management needs improvement. Capital expenditure is a key area needing attention, as it impacts overall financial health. Despite these challenges, Alkem's strong performance in core areas positions it well for future growth and stability within the healthcare industry.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Neutral

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Neutral

P/E RATIO (TTM)

29.40

Neutral

Industry Median

28.62

Neutral
Neutral

Mid Cap Median

36.34

Neutral

P/E RATIO

27.91

P/B RATIO

4.65

Overvalued

Industry Median

3.17

Overvalued
Undervalued

Mid Cap Median

7.64

Undervalued

P/S RATIO

4.41

Overvalued

Industry Median

3.42

Overvalued
Undervalued

Mid Cap Median

6.30

Undervalued

Others

Overvalued

PEG RATIO

3.60

Overvalued
Overvalued

EV/EBITDA RATIO

18.77

Overvalued

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹5373.5 as on Jun 19, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 10.00

Alkem Laboratories demonstrates outstanding growth across all key metrics. Revenue, operating profit, EPS, assets, and net income are all growing at high rates. This reflects strong market positioning, effective management strategies, and a robust ability to capitalize on opportunities. The company's consistent growth underscores its financial health and potential for future success.

ExcellentRevenue Growth RateExcellent
ExcellentOperating Profit Growth RateExcellent
ExcellentEarnings Per Share (EPS) GrowthExcellent
ExcellentAsset Growth RateExcellent
ExcellentNet Income Growth RateExcellent
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate19.959.079.222.3413.47
Operating Profit Growth Rate5.6-21.0338.6611.6919.63
Earnings Per Share (EPS) Growth3.82-40.1982.4720.596.29
Asset Growth Rate22.14-2.2213.2213.5917.99
Net Income Growth Rate3.83-40.0679.8422.316.14
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 8.40

Alkem Laboratories demonstrates a strong financial performance with high adjusted EPS, cash EPS, and book value per share. The company's dividend per share is also robust, reflecting its commitment to returning value to shareholders. However, the high capital expenditures indicate significant investments, which need to be carefully managed to ensure they yield positive returns. Overall, the company exhibits solid financial health with areas needing focused attention.

ExcellentAdjusted Earnings Per Share (Adjusted EPS)Excellent
ExcellentCash Earnings Per Share (Cash EPS)Excellent
ExcellentBook Value Per ShareExcellent
ExcellentDividend Per Share (DPS)Excellent
PoorCapital Expenditures (CapEx)Poor
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)143.7593.25160.5188.42211.42
Cash Earnings Per Share (Cash EPS)165.33109.75175.83214.33227.75
Book Value Per Share719.83753.75859.33998.751151.67
Dividend Per Share (DPS)34.4150.2140.5545.2853.9
Capital Expenditures (CapEx)328230187635487
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 10.00

Alkem Laboratories exhibits outstanding profitability across all key metrics. High gross profit margins, ROCE, ROE, ROA, operating margins, and net margins demonstrate efficient operations and strong financial performance. The company effectively manages its costs and generates substantial profits from its revenue. This robust profitability underscores the company's financial health and competitive advantage.

ExcellentGross Profit MarginExcellent
ExcellentReturn on Capital Employed (ROCE)Excellent
ExcellentReturn on Equity (ROE)Excellent
ExcellentReturn on Assets (ROA)Excellent
ExcellentOperating MarginExcellent
ExcellentNet MarginExcellent
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin16.4611.3115.3916.6217.83
Return on Capital Employed (ROCE)1814202021
Return on Equity (ROE)19.4511.1317.5618.4817.01
Return on Assets (ROA)14.611.7914.4414.214.4
Operating Margin19.3213.9817.7519.3820.43
Net Margin15.88.6814.317.0815.98
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 3.67

Alkem Laboratories faces significant challenges in its efficiency. All turnover ratios are low, suggesting potential issues with asset utilization and operational processes. The company needs to improve how it uses its assets to generate revenue. The extended days sales in inventory and receivable days indicate slow inventory turnover and collections, which could tie up working capital and affect cash flow. Boosting operational efficiency will be crucial for enhancing overall performance.

WeakFixed Asset Turnover RatioWeak
WeakInventory Turnover RatioWeak
AverageReceivables Turnover RatioAverage
PoorDays Sales in Inventory RatioPoor
WeakReceivable DaysWeak
PoorCapital Turnover RatioPoor
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio3.664.324.414.553.66
Inventory Turnover Ratio3.343.664.073.873.87
Receivables Turnover Ratio6.095.775.785.495.4
Days Sales in Inventory Ratio109.2899.7389.6894.3294.32
Receivable Days59.9363.2663.1566.4867.59
Capital Turnover Ratio1.221.271.21.031
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 9.20

Alkem Laboratories exhibits strong coverage ratios, indicating a robust ability to meet its interest and dividend obligations. The company comfortably covers its interest expenses with its earnings, and its equity dividend coverage is also solid. This reflects prudent financial management and a low risk of financial distress. The company's financial stability is enhanced by its ability to service its debts and dividends effectively.

ExcellentInterest Coverage RatioExcellent
GoodEquity Dividend Coverage RatioGood
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage Ratio36.4613.219.0621.7118.83
Equity Dividend Coverage Ratio41.643.743.57
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

Alkem Laboratories exhibits excellent solvency, indicating a strong and stable financial structure. The company maintains very low levels of debt relative to equity and assets, reflecting a conservative approach to financial leverage. This strong equity base provides a solid foundation for future growth and resilience against economic downturns. The company's financial risk is minimized due to its robust solvency position, enhancing its long-term sustainability.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0.010.010.020.050.06
Debt to Equity Ratio0.010.010.020.050.06
Equity Ratio0.990.990.980.950.94
Debt To Asset Ratio0.010.010.020.040.04
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 7.46

Alkem Laboratories demonstrates a mixed liquidity profile. While the quick ratio indicates a strong ability to meet short-term obligations with highly liquid assets, the current ratio suggests there is room for improvement in managing current assets and liabilities. The cash ratio, being average, points to moderate cash reserves. The operating cash flow ratio is weak, indicating challenges in generating sufficient cash from operations to cover current liabilities. Overall, the company maintains high liquidity but optimizing cash flow from its operations will be beneficial.

GoodCurrent RatioGood
ExcellentQuick RatioExcellent
AverageCash RatioAverage
WeakOperating Cash Flow RatioWeak
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio1.962.192.42.452.42
Quick Ratio1.41.631.871.881.88
Cash Ratio0.480.570.310.310.28
Operating Cash Flow Ratio0.210.360.390.380.32
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 13 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Abbott India Ltd8.6835.89Neutral1892.00730.391552.00
2Glaxosmithkline Pharmaceuticals Ltd8.3838.14Neutral1309.0059.731036.00
3J B Chemicals & Pharmaceuticals Ltd8.1449.64Overvalued1107.0041.98709.00
4Alkem Laboratories Ltd8.0827.91Neutral3005.00182.762351.00
5Gland Pharma Ltd7.9135.27Overvalued1630.0078.881027.00
6Lupin Ltd7.8420.16Neutral8816.00139.255355.00
7Ajanta Pharma Ltd7.7236.27Neutral1395.0075.781056.00
8Mankind Pharma Ltd7.6152.10Highly Overvalued3617.0049.341938.00
9Zydus Lifesciences Ltd7.6021.38Neutral8475.0035.385124.00
10Laurus Labs Ltd7.1085.84Neutral1778.0013.72890.00
11Dr Reddys Laboratories Ltd6.4925.31Neutral6454.0038.584158.00
12Glenmark Pharmaceuticals Ltd6.3645.87Neutral4572.00-7.121362.00
13Ipca Laboratories Ltd6.3335.26Neutral1979.0044.641184.00
Management Assessment Summary
OrangeBalanced Management

Alkem Laboratories demonstrates mixed management effectiveness. The company exhibits strong profit growth and consistent dividend payouts, which are positive indicators. However, there are concerns regarding declining sales growth and increasing working capital days. While ROCE is healthy, the decrease in promoter holding is also a point of concern. Overall, the management's effectiveness is rated as mixed, requiring attention to sales and operational efficiency to ensure sustainable growth and profitability.

Category Metric Value Assessment
PROS Strong Profit Growth 14% (5Y) Profit growth is strong over the long term
Consistent Dividend Payout 25% (Mar 2025) Company consistently shares profits with shareholders
CONS Declining Sales Growth 2.34% (Mar 2025) Sales growth has slowed down recently
Increasing Working Capital Days 172 (Mar 2025) Working capital management shows signs of inefficiency
AverageFinancial Performance & GrowthAverage
GoodCapital Efficiency & ReturnsGood
AverageFinancial Health & PrudenceAverage
AverageShareholding & Ownership StructureAverage
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Shareholding & Ownership Structure

Risk Assessment Summary
OrangeBalanced Risk

Alkem Laboratories faces a moderate risk profile. An increase in working capital days points to potential operational inefficiencies. A decreasing promoter holding and increasing competition, as indicated by peer comparison, are also concerning. However, the company maintains a reasonable debt level and interest coverage. Given these factors, the overall risk is assessed as moderate, requiring careful monitoring of working capital management and competitive dynamics.

AverageSegment performance volatilityAverage
AverageForeign exchange or interest rate exposureAverage
AverageRegulatory compliance cost trendsAverage
01.

Segment performance volatility

02.

Foreign exchange or interest rate exposure

03.

Regulatory compliance cost trends

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 105367.45Bullish
  3. SMA 205357.82Bullish
  4. SMA 505339.70Bullish
  5. EMA 105366.81Bullish
  6. EMA 205359.79Bullish
  7. EMA 505348.85Bullish
  8. DEMA 105374.46Bullish
  9. DEMA 205371.03Bullish
  10. DEMA 505356.19Bullish
  11. TEMA 105376.20Bullish
  12. TEMA 205374.28Bullish
  13. TEMA 505372.66Bullish
  14. MACD8.64Bullish
  15. ADX12.65Weak Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI58.52Neutral
  3. CCI135.24Overbought
  4. ROC 90.67Bullish
  5. ROC 140.77Bullish
  6. ROC 250.63Bullish
  7. Stoch K61.71Neutral
  8. Stoch D53.11Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper5385.82Neutral
  3. BB Middle5357.82Neutral
  4. BB Lower5329.83Neutral
  5. ATR29.41Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI55.30Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 105361.25Bullish
  3. SMA 205350.75Bullish
  4. SMA 505328.65Bullish
  5. EMA 105363.87Bullish
  6. EMA 205353.16Bullish
  7. EMA 505349.00Bullish
  8. DEMA 105376.26Bullish
  9. DEMA 205368.22Bullish
  10. DEMA 505333.65Bullish
  11. TEMA 105379.04Bullish
  12. TEMA 205377.77Bullish
  13. TEMA 505352.88Bullish
  14. MACD11.92Bullish
  15. ADX32.46Strong Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI57.63Neutral
  3. CCI155.10Overbought
  4. ROC 90.60Bullish
  5. ROC 140.73Bullish
  6. ROC 251.43Bullish
  7. Stoch K61.83Neutral
  8. Stoch D66.80Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper5384.21Neutral
  3. BB Middle5350.75Neutral
  4. BB Lower5317.29Neutral
  5. ATR38.73Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI68.71Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 105349.95Bullish
  3. SMA 205340.20Bullish
  4. SMA 505375.36Bullish
  5. EMA 105351.32Bullish
  6. EMA 205345.33Bullish
  7. EMA 505367.99Bullish
  8. DEMA 105365.54Bullish
  9. DEMA 205341.31Bullish
  10. DEMA 505334.42Bullish
  11. TEMA 105374.37Bullish
  12. TEMA 205363.01Bullish
  13. TEMA 50N/AN/A
  14. MACD0.25Bullish
  15. ADX23.44Weak Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI54.58Neutral
  3. CCI90.28Neutral
  4. ROC 90.95Bullish
  5. ROC 141.79Bullish
  6. ROC 252.58Bullish
  7. Stoch K67.63Neutral
  8. Stoch D54.38Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper5393.47Neutral
  3. BB Middle5340.20Neutral
  4. BB Lower5286.93Neutral
  5. ATR67.92Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI66.00Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (22)
  1. IndicatorValueSignal
  2. SMA 105326.40Bullish
  3. SMA 205350.20Bullish
  4. SMA 505420.89Bearish
  5. SMA 1005470.61Bearish
  6. SMA 2005519.44Bearish
  7. EMA 105339.85Bullish
  8. EMA 205356.78Bullish
  9. EMA 505401.94Bearish
  10. EMA 1005441.87Bearish
  11. EMA 2005432.82Bearish
  12. DEMA 105335.12Bullish
  13. DEMA 205318.90Bullish
  14. DEMA 505342.81Bullish
  15. DEMA 1005405.00Bearish
  16. DEMA 2005503.08Bearish
  17. TEMA 105356.15Bullish
  18. TEMA 205313.65Bullish
  19. TEMA 505326.61Bullish
  20. TEMA 1005330.07Bullish
  21. TEMA 2005440.49Bearish
  22. MACD-26.24Bullish
  23. ADX16.27Weak Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI50.21Neutral
  3. CCI-2.16Neutral
  4. ROC 14-2.29Bearish
  5. ROC 25-1.66Bearish
  6. Stoch K42.13Neutral
  7. Stoch D32.39Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper5494.75Neutral
  3. BB Middle5350.20Neutral
  4. BB Lower5205.65Neutral
  5. ATR125.20Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI48.31Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Market Sentiment

Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bearish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (10)
  1. IndicatorValueSignal
  2. SMA 205430.45Bearish
  3. SMA 505429.79Bearish
  4. EMA 205429.79Bearish
  5. EMA 505405.16Bearish
  6. DEMA 205395.03Bearish
  7. DEMA 505511.98Bearish
  8. TEMA 205335.75Bearish
  9. TEMA 505440.82Bearish
  10. MACD-31.29Bearish
  11. ADX14.76Weak Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI47.53Neutral
  3. CCI-41.94Neutral
  4. ROC 14-4.20Bearish
  5. ROC 25-4.64Bearish
  6. Stoch K38.40Neutral
  7. Stoch D44.51Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper5696.92Neutral
  3. BB Middle5430.45Neutral
  4. BB Lower5163.98Neutral
  5. ATR306.67Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI52.49Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 65503.42Bearish
  3. SMA 125409.22Bullish
  4. SMA 245387.32Bullish
  5. EMA 65465.48Bullish
  6. EMA 125415.47Bullish
  7. EMA 245220.28Bullish
  8. DEMA 65485.22Bullish
  9. DEMA 125540.23Bearish
  10. DEMA 245679.24Bearish
  11. TEMA 65452.63Bullish
  12. TEMA 125484.63Bullish
  13. TEMA 245578.21Bearish
  14. MACD616.31Bearish
  15. ADX27.73Strong Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI58.82Neutral
  3. CCI72.36Neutral
  4. ROC 2513.76Bullish
  5. ROC 5051.85Bullish
  6. Stoch K52.71Neutral
  7. Stoch D60.32Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper5958.33Neutral
  3. BB Middle5338.58Neutral
  4. BB Lower4718.83Neutral
  5. ATR534.46Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI71.94Neutral